Literature DB >> 8748009

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view.

J Verweij1, H T Mouridsen, O S Nielssen, P J Woll, R Somers, A T van Oosterom, M Van Glabbeke, T Tursz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8748009     DOI： 10.1016/1040-8428(94)00146-K

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  10 in total

1.  Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy.

Authors:  Yoshiaki Kinebuchi; Wataru Noguchi; Yasuhiko Igawa; Osamu Nishizawa
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

2.  Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

Authors:  Revathi Suppiah; Laura Wood; Paul Elson; George T Budd
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

3.  The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.

Authors:  Paolo Andrea Zucali; Alexia Bertuzzi; Hector Jose Soto Parra; Elisabetta Campagnoli; Vittorio Quagliuolo; Armando Santoro
Journal:  Invest New Drugs       Date:  2007-09-25       Impact factor: 3.850

4.  Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.

Authors:  Elisa Stroppa; Alexia Bertuzzi; Gabriele Di Comite; Chiara Mussi; Romano Fabio Lutman; Alfredo Barbato; Armando Santoro
Journal:  Invest New Drugs       Date:  2009-07-07       Impact factor: 3.850

5.  Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.

Authors:  E J O Soini; B García San Andrés; T Joensuu
Journal:  Ann Oncol       Date:  2010-07-13       Impact factor: 32.976

6.  Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Authors:  G Huygh; Paul M J Clement; H Dumez; P Schöffski; H Wildiers; J Selleslach; J M Jimeno; I De Wever; R Sciot; L Duck; A T Van Oosterom
Journal:  Sarcoma       Date:  2006-12-31

7.  High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

Authors:  O S Nielsen; P Dombernowsky; H Mouridsen; D Crowther; J Verweij; J Buesa; W Steward; S Daugaard; M van Glabbeke; A Kirkpatrick; T Tursz
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

8.  The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.

Authors:  Bernd Kasper; Thomas Schmitt; Patrick Wuchter; Antonia Dimitrakopoulou-Strauss; Anthony D Ho; Gerlinde Egerer
Journal:  Mar Drugs       Date:  2009-07-17       Impact factor: 5.118

9.  New drugs and combinations for the treatment of soft-tissue sarcoma: a review.

Authors:  Neeta Somaiah; Margaret von Mehren
Journal:  Cancer Manag Res       Date:  2012-11-23       Impact factor: 3.989

10.  Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  O S Nielsen; P Dombernowsky; H Mouridsen; S Daugaard; M Van Glabbeke; A Kirkpatrick; J Verweij
Journal:  Sarcoma       Date:  2000
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.